CurrentCignaPolicy IP0584

Attention Deficit Hyperactivity Disorder (ADHD) Stimulants for Individual and Family Plans

Cigna drug coverage policy (IP0584) defining medical necessity, preferred-product step therapy, reauthorization, authorization durations, and not-covered uses for specified CNS stimulant products (multiple brand and generic formulations) for individual and family plans.

Policy Summary

PayerCigna

PolicyAttention Deficit Hyperactivity Disorder (ADHD) Stimulants for Individual and Family Plans

Policy CodePolicy IP0584

Change TypeMultiple product additions and preferred-product updates

Effective DateFeb 15, 2026

Next Review Date

Key ActionApproval requires documentation of diagnosis and the specified prior trial(s), failures, contraindications, or intolerances for the requested stimulant product as detailed in product-specific criteria.

SourceLink

POLICY UPDATE CHANGES

Added criteria for dextroamphetamine immediate-release tablets, methylphenidate ER tablets (45mg, 63mg, and 72mg), Relexxii, and Zenzedi.

Added criteria for Metadate CD.

Removed methylphenidate extended-release capsules (generic for Aptensio XR) from the list of alternatives in the preferred product criteria for Metadate CD, methylphenidate ER 45/63/72 mg, and Relexxii.

Added Adzenys XR-ODT and amphetamine extended-release orally disintegrating tablets (generic for Adzenys XR-ODT) to the policy and updated preferred product statements and Vyvanse capsule/chewable preferred product requirements.

MultipleProducts covered (brand and generics)

Up to 12 monthsInitial authorization duration

Up to 12 months

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.